bioAffinity Technologies Raises $4M in At-the-Market Private…

Event summary

bioAffinity Technologies raised approximately $4 million through a private placement offering priced at-the-market under Nasdaq rules.
The deal involved the sale of 8,462,027 shares of common stock (or pre-funded warrants) and two warrants to purchase up to an aggregate 16,924,054 shares of common stock.
WallachBeth Capital LLC acted as the sole placement agent for the offering, which is expected to close on or about August 14, 2026.
The combined effective offering price for each share of common stock and accompanying two warrants is $0.4727.

The big picture

This $4 million private placement reflects a strategic move by bioAffinity Technologies to bolster its financial position amid a competitive landscape in noninvasive diagnostics. The deal underscores the ongoing reliance on at-the-market offerings as a flexible financing tool for biotech firms, particularly those focused on early-stage cancer detection technologies.

What we're watching

Execution Risk: Whether bioAffinity Technologies can successfully close the offering by August 14, 2026, and meet customary closing conditions.
Market Dynamics: How the $4 million capital raise will impact bioAffinity's strategic initiatives in noninvasive diagnostics and early cancer detection.
Regulatory Compliance: The pace at which bioAffinity Technologies can secure registration rights for the shares of common stock underlying the warrants.